Clinical trials
for patients

The objective of Part 1 of this clinical trial is to find the best dose of elranatamab when given in combination with a second drug, daratumumab. In Part 2 of this study, the safety and efficacy of the study drug, elranatamab, will be studied in patients with relapsed or unresponsive multiple myeloma after previous treatment. In this Part 2 of the study, in order to evaluate different administration patterns, participants will be divided into 3 groups: group A, which will receive increasing dose...

This research study (clinical trial) will evaluate the safety and effects, positive or negative, of pralsetinib compared to the reference treatment chosen by the study doctor with vandetanib or cabozantinib to determine if it is an effective way to treat TNBC. Pralsetinib was designed to treat patients with cancers that have alterations in the RET gene that can cause the tumor to grow. Variations in RET (called RET mutations) are frequently detected in TNBC. Preliminary data from clinical studie...

This Phase 1/2 study is being conducted to analyze the effects of AMG 510 in the treatment of advanced solid tumors with the p.G12C mutation in KRAS.

The main objective of this study is to evaluate the efficacy of MRTX849 in monotherapy and in combination with pembrolizumab administered in a first-line treatment setting to patients with advanced non-small cell lung cancer (NSCLC) with a specific modification in tumor genes (KRAS G12C mutation).

The purpose of this clinical trial is to evaluate whether the AMX-818 trial drug, alone or in combination with pembrolizumab at different doses, is safe and effective in treating human cancers that produce a protein called HER2 and to learn how your body processes and reacts to the trial drug.

The main objective of this study is to demonstrate that ALT-L9 works as well as the approved/marketed drug Eylea® for patients with AMDEn. Eylea® is a marketed drug that has been approved for the treatment of AMDEn. Eylea® and ALT-L9 contain the same active ingredient, aflibercept.

The purpose of this study is to evaluate a drug called Epcoritamab in combination with other drugs that are used to treat non-Hodgkin's lymphoma (NHL). Epcoritamab might work better when combined with other drugs that treat cancer in different ways

The purpose of this trial is to evaluate and determine the efficacy of pemigatinib in participants with recurrent glioblastoma or other CNS tumors with alterations in the FGFR1, FGFR2 or FGFR3 genes.

The objective of this study is to investigate how Niraparib works in the treatment of women with newly diagnosed ovarian cancer before the first major surgery. Information will be obtained on whether Niraparib works in the treatment of their disease by either delaying or preventing recurrence when compared to the current reference treatment. It will also be investigated whether it is safe, and what is the most appropriate dose.